MedinCell

medincell.com

MedinCell
MedinCell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDINCELL GRANTED €17M TO DEVELOP CHEAP LONG-ACTING CONTRACEPTION

Labiotech.eu | November 29, 2019

news image

The French company MedinCell has received a €17.3M ($19M) grant from the Bill and Melinda Gates Foundation to advance its long-acting contraceptive implant to human trials. The grant is a follow-on to a €3.2M endowment from the Gates Foundation in 2017 to fuel early preclinical development of the implant. The additional funds will help MedinCell to advance the contraceptive through preclinical development and into a phase I trial. The cash will be available in installments; MedinCell c...

Read More

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

news image

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More

Business Insights, PHARMACY MARKET

MEDINCELL’S PARTNER TEVA ANNOUNCES SUCCESSFUL LAUNCH OF UZEDY™

Businesswire | August 03, 2023

news image

MedinCell During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1 “We are actually right on plan or slightly ahead of our market access strategy targets and we are very happy with the launch.&r...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

MEDINCELL GRANTED €17M TO DEVELOP CHEAP LONG-ACTING CONTRACEPTION

Labiotech.eu | November 29, 2019

The French company MedinCell has received a €17.3M ($19M) grant from the Bill and Melinda Gates Foundation to advance its long-acting contraceptive implant to human trials. The grant is a follow-on to a €3.2M endowment from the Gates Foundation in 2017 to fuel early preclinical development of the implant. The additional funds will help MedinCell to advance the contraceptive through preclinical development and into a phase I trial. The cash will be available in installments; MedinCell c...

Read More
news image

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More
news image

Business Insights, PHARMACY MARKET

MEDINCELL’S PARTNER TEVA ANNOUNCES SUCCESSFUL LAUNCH OF UZEDY™

Businesswire | August 03, 2023

MedinCell During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1 “We are actually right on plan or slightly ahead of our market access strategy targets and we are very happy with the launch.&r...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us